Accretion Pharmaceuticals Limited IPO

Apply 0
Avoid 0

Don't Miss It! Mark Your Calender Now:


Accretion Pharmaceuticals Limited is a contract development and manufacturing organization (CDMO) engaged in the manufacturing and marketing of a broad spectrum of pharmaceutical formulations including tablets, capsules, oral liquids, external preparations (ointments, creams, gels, lotions, medicated shampoos, mouthwash, dusting powders), and oral powders (sachets and dry syrups).

The company offers end-to-end pharmaceutical manufacturing services, including:
i. Own branded formulations for direct sales in domestic and select export markets,
ii. Loan license manufacturing for merchant exporters,
iii. Contract manufacturing for various third-party marketers and corporate clients.

Export Footprint

While the company is based in India, it has established a strong presence in international markets through merchant exporters and direct exports. A major portion of Accretion’s output is currently exported—either directly or indirectly—to Africa, South-East Asia, and Latin America, markets known for high demand in cost-effective generics and OTC products.

The company operates across three primary verticals:
i. Domestic Branded Sales – Products marketed under in-house or client brands within India.
ii. Direct Export Sales – Branded products exported directly to overseas buyers.
iii. Merchant Export Model (Loan License) – Products manufactured on loan license for merchant exporters who handle international sales.

Objects of the Accretion Pharmaceuticals Limited IPO:

IPO proposes to utilise the Net Proceeds from the Issue towards the following objects: i. Capital expenditure towards purchase of new equipment/ machineries, etc. ii. Capital expenditure towards upgradation of existing manufacturing facility. iii. Repayment/prepayment of certain borrowings availed by the Company. iv. Funding working capital requirements. v. General Corporate Purpose.

Accretion Pharmaceuticals Limited IPO Details:

Open Date: May 14 2025
Close Date: May 16 2025
Total Shares: 29,46,000
Face Value: ₹ 10 Per Equity Share
Issue Size: 29.75 Cr.
Lot Size: 1200 Shares
Issue Price: ₹ 96 - 101 Per Equity Share
Listing At: NSE Emerge
Listing Date: May 21 2025

Promoters And Management:

Mr. Mayur Popatlal Sojitra, aged 37, is a Promoter and Executive Director of the Company. A former partner at M/s Accretion Pharmaceuticals, he has over 12 years of experience in manufacturing and trading pharmaceutical, nutraceutical, and Ayurvedic products. He holds a B.Pharm from Gujarat University and an MBA in International Business from the University of Greenwich, London. His global education and industry expertise drive the company’s strategic expansion into regulatory markets. Mr. Harshad Nanubhai Rathod, aged 38, is the Executive Director and CFO of the Company. He holds a B.Pharm from Gujarat University and an MBA from Madhyanchal Professional University, Bhopal. With over 14 years of experience in the pharmaceutical industry, including his tenure as Marketing Head at Recspeed Healthcare, he plays a key role in financial planning, strategic growth, and team leadership at Accretion Pharmaceuticals Limited. Mr. Vivek Ashok Kumar Patel, aged 37, is the Managing Director of the Company. He holds an MBA in Pharma from DY Patil Institute, Mumbai, and has over 14 years of experience in pharmaceutical production and marketing. After hands-on training at Alive Pharma, he worked as a Marketing Executive at Merck Ltd., where he gained valuable insights into marketing, logistics, and finance. His diverse experience adds strategic depth to the company’s leadership.

Financials of Accretion Pharmaceuticals Limited IPO:

To be updated shortly.

Comparison With Peers:

To be updated shortly.

Recommendation on Accretion Pharmaceuticals Limited IPO:

To be updated shortly.

Lead Manager of Accretion Pharmaceuticals Limited IPO:

  1. Jawa Capital Services Private Limited

Registrar of Accretion Pharmaceuticals Limited IPO:

  1. Kfin Technology Private Limited

Company Address:

Accretion Pharmaceuticals Limited 29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvad Sanand, Phone: +91-97148 82929 Email: compliance@accretionpharma.com Website: https://accretionpharma.com/

Discussion on Accretion Pharmaceuticals Limited IPO:

Leave a Reply